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1Intracerebral hemorrhage (ICH) is still the deadliest type of stroke and accounts for 10% to 20% of all cerebrovascular 
events.1,2 Hematoma expansion occurs in about one third of 
patients and is strongly associated with poor outcome.3 As a 
potentially modifiable determinant of ICH prognosis, hema-
toma expansion represents an appealing target for acute ICH 
treatment.4
The relationship between acute inflammation, white blood 
cell (WBC) count and ICH pathophysiology is complex. ICH 
is associated with leukocytosis, but the inflammatory acti-
vation represented by leukocytosis may, in turn, play a role 
in ICH severity. The results of multiple studies suggest that 
higher WBC counts accompany more severe ICH as measured 
by reduced consciousness, higher baseline hematoma volume, 
and intraventricular hemorrhage presence.5,6 Leukocyte count 
has also been associated with higher risk of early neurological 
deterioration, increased long-term mortality, and poor func-
tional outcome.7–9 However, Di Napoli et al10 found that leu-
kocytosis does not independently predict poor ICH prognosis 
when controlling for other outcome determinants including 
age, baseline hematoma volume, and admission Glasgow 
Coma Scale.
Leukocytes interact with platelets, endothelium, and coagu-
lation factors and have been widely recognized as important 
contributors to facilitating hemostasis in physiological and 
pathological conditions.11–13 Acute leukocytosis shifts the 
hemostatic balance in favor of coagulation and may therefore 
play an important role in the arrest of bleeding after an ICH 
occurs. To test the hypothesis that acute leukocytosis limits the 
extent of bleeding after acute ICH, we investigated whether 
acute leukocytosis reduced the risk of subsequent hematoma 
expansion.
Background and Purpose—Acute leukocytosis is a well-established response to intracerebral hemorrhage (ICH). 
Leukocytes, because of their interaction with platelets and coagulation factors, may in turn play a role in hemostasis. We 
investigated whether admission leukocytosis was associated with reduced bleeding after acute ICH.
Methods—Consecutive patients with primary ICH were prospectively collected from 1994 to 2015 and retrospectively 
analyzed. We included subjects with a follow-up computed tomographic scan available and automated complete white 
blood cell count performed within 48 hours from onset. Baseline and follow-up hematoma volumes were calculated 
with semiautomated software, and hematoma expansion was defined as volume increase >30% or 6 mL. The association 
between white blood cell count and ICH expansion was investigated with multivariate logistic regression.
Results—A total of 1302 subjects met eligibility criteria (median age, 75 years; 55.8% men), of whom 207 (15.9%) 
experienced hematoma expansion. Higher leukocyte count on admission was associated with reduced risk of hematoma 
expansion (odds ratio for 1000 cells increase, 0.91; 95% confidence interval, 0.86–0.96; P=0.001). The risk of hematoma 
expansion was inversely associated with neutrophil count (odds ratio, 0.90; 95% confidence interval, 0.85–0.96; P=0.001) 
and directly associated with monocyte count (odds ratio, 2.71; 95% confidence interval, 1.08–6.83; P=0.034). There was 
no association between lymphocyte count and ICH expansion (odds ratio, 0.96; 95% confidence interval, 0.79–1.17; 
P=0.718).
Conclusions—Higher admission white blood cell count is associated with lower risk of hematoma expansion. This 
highlights a potential role of the inflammatory response in modulating the coagulation cascade after acute ICH.  
(Stroke. 2016;47:00-00. DOI: 10.1161/STROKEAHA.116.013176.)
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Methods
Patient Selection
Institutional review board approval was received for all the proce-
dures of this research. Subjects for the present analysis were selected 
from an ongoing prospectively collected cohort of patients with pri-
mary ICH, admitted to our Institution from 1994 to 2015.14,15 Patients 
were included if they presented with (1) diagnosis of spontaneous 
ICH on noncontrast computed tomographic scan (NCCT), obtained 
within 48 hours from onset, (2) available follow-up NCCT, and (3) 
complete WBC performed within 48 hours from onset. Exclusion 
criteria were as follows: (1) evidence of traumatic intracranial bleed-
ing, (2) neoplastic or vascular lesion presumed to be the underlying 
cause of the hemorrhage, (3) intracranial bleeding secondary to hem-
orrhagic transformation of ischemic stroke, (4) primary intraventricu-
lar hemorrhage, (5) missing clinical and demographic information, 
and (6) surgical evacuation of the hematoma performed before the 
follow-up NCCT scan. All the subjects eligible for the study were 
stratified in quartiles according to the median and interquartile values 
of WBC count. Admission leukocytosis was defined as total WBC 
count >11 000 cells/μL.6
Image Acquisition and Analysis
NCCT scans were obtained using an axial technique, with the fol-
lowing acquisition parameters: 120 to 140 kVp, 100 to 500 mA, and 
5-mm slice thickness reconstruction. Baseline and follow-up ICH 
volumes were obtained analyzing NCCT images with a semiauto-
mated computer assisted technique (Analyze Direct 11.0 software). 
Hematoma expansion was defined as an absolute volume increase >6 
mL or a relative volume increase >30% from baseline ICH volume.16
Clinical Variables
Clinical and demographic data were acquired through patient or 
family members’ interviews or with retrospective review of hospital 
charts. We collected the following information: medical history of 
hypertension, diabetes mellitus, hypercholesterolemia, antiplatelet 
therapy, oral anticoagulant treatment. Time from symptom onset to 
NCCT and WBC blood samples, admission platelet count, activated 
partial thromboplastin time, and international normalized ratio were 
also measured.
Statistical Analyses
Continuous variables were expressed as median (interquartile range) 
and categorical variables as count (percentage). Differences in con-
tinuous variables and categorical variables across WBC quartiles 
were examined with Kruskal–Wallis test and χ2 test, respectively. 
The association between total and differential WBC count and the 
risk of hematoma expansion was investigated with a multivariable 
binary logistic regression model, adjusted for previously identified 
predictors of hematoma expansion17 and variables with a P<0.1 in the 
univariate analysis comparing WBC quartiles.
Single subjects’ predicted probability of hematoma expansion was 
derived from individual data and from the binary logistic regression 
model estimates and expressed as a continuous variable ranging from 
0 to 1. P<0.05 were considered statistically significant, and all the 
analyses were performed using SPSS version 21, 2012 (www.spss.
com).
Results
After application of the inclusion and exclusion criteria, 1302 
patients (median age, 75 years; interquartile range, 64–82; 
55.8% men) were included in the analysis (Figure 1). Table 1 
shows the demographic and clinical characteristics of the 
study population. The median WBC count on admission was 
9200 cells/μL (interquartile range, 7100–11 700), and 413 
(31.7%) patients had admission leukocytosis. A total of 207 
patients (15.9%) experienced hematoma expansion. Excluded 
patients were more likely to have infratentorial hematomas, 
were more often women and on antiplatelet medications, and 
were less likely to have a positive medical history of hyper-
tension and hypercholesterolemia (P<0.05). In addition, the 
excluded patients had larger baseline hematoma volume and 
higher admission WBC count (all P<0.05).
Individuals with the highest WBC had higher platelet 
counts and a trend toward shorter activated partial thrombo-
plastin time. In addition, they had significantly larger baseline 
hematoma volume and longer time from symptom onset to 
NCCT and WBC blood sample (Table 2). Hematoma expan-
sion rate was significantly higher in those individuals with 
the lowest WBC and progressively decreased with increasing 
WBC quartiles (P=0.027).
Hematoma Expansion Analysis
After adjustment for established predictors of hematoma 
expansion, higher admission WBC count was independently 
associated with reduced risk of hematoma expansion (odds 
ratio for 1000 cells increase, 0.91; 95% confidence interval, 
0.86–0.96; P=0.001). To determine whether the effect was 
driven by a particular subset of WBC, we analyzed neutro-
phil, lymphocyte, and monocyte count separately. Increased 
neutrophil count was associated with lower risk of hematoma 
expansion (odds ratio for 1000 cells increase, 0.90; 95% con-
fidence interval, 0.85–0.96; P=0.001). Conversely, higher 
admission monocyte count was an independent predictor of 
hematoma expansion (odds ratio for 1000 cells increase, 2.71; 
95% confidence interval, 1.08–6.83; P=0.034). There was no 
detectable association between lymphocyte count and hema-
toma expansion (odds ratio for 1000 cells increase, 0.96; 95% 
confidence interval, 0.79–1.17; P=0.718). Table 3 shows the 
results of the multivariate regression model and all results 
were unchanged when admission platelet count, activated 
partial thromboplastin time, time from onset to WBC blood 
sample, and the presence of intraventricular hemorrhage were 
also included in the multivariate analysis.
The predicted probability of hematoma expansion was 
inversely correlated with neutrophil count, and directly cor-
related with monocyte count, in a linear, dose-dependent rela-
tionship (Figure 2).
Discussion
The different effect of neutrophils and monocytes on hema-
toma expansion is the most striking result of our study. Higher 
neutrophil count is associated with reduced risk of hematoma 
expansion, as opposed to monocyte count that correlates with 
higher risk.
From a pathophysiological standpoint, our results provide 
further insights into the complex relationship between acute 
inflammation and ICH, raising the intriguing hypothesis that 
the inflammatory response in the hyperacute phase of the dis-
ease not only is a nonspecific stress-related reaction but may 
also be beneficial for ICH patients, improving the coagulation 
response and limiting hematoma expansion.
Leukocytes interact with platelets, endothelium, and coagu-
lation factors18 and therefore may play an important role in 
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hematoma expansion pathophysiology, through modulation 
of the coagulation system.19 This hypothesis is indirectly sup-
ported by our observation of a progressively higher platelet 
count and shorter activated partial thromboplastin time with 
increasing WBC quartiles.
Neutrophils are the first inflammatory cells to invade the 
central nervous system when an ICH occurs.20 Beyond the 
well-known inflammatory and antimicrobial actions, neu-
trophils have been increasingly recognized as important 
contributors to several physiological processes. In particu-
lar, activated neutrophils exhibit significant procoagulant 
properties.21–23 First, neutrophils shift the coagulation bal-
ance in favor of thrombus formation through significant 
expression and release of tissue factor.24 Second, neutro-
phils indirectly increase the amount of active tissue fac-
tor downregulating the tissue factor pathway inhibitor.25 
Third, neutrophil extracellular traps can activate platelets, 
factor X and factor XII, enhance thrombin generation, and 
contribute to stabilization of the fibrin clot as well.25–27 
Neutrophils’ activation in the hyperacute ICH phase may 
therefore promote a procoagulant state that limits hema-
toma expansion.
Conversely, the monocyte surface is rich with strong physi-
ological anticoagulants like thrombomodulin and tissue factor 
pathway inhibitor.28–30 Therefore, it is biologically plausible 
that monocyte activation may interfere with clot formation 
and fibrin stabilization and facilitate further bleeding.
In addition, monocyte activation in animal models and 
absolute monocyte count in humans were associated with 
poor outcome after ICH.31–33 A previous report hypothesized 
that hematoma expansion may be the link between elevated 
monocyte count and poor ICH outcome, although this associa-
tion was not statistically significant.33 Our results confirm this 
hypothesis, showing that monocyte count is associated with 
increased odds of hematoma expansion. Further evidence 
supporting the association between monocytes and hematoma 
expansion comes from preclinical data obtained in a mouse 
model of ICH. Yao et al34 found that a deficiency of the CCL2-
CCR2 monocyte chemoattractant system was associated with 
decreased extent of bleeding after intracranial injection of 
bacterial collagenase.
We observed that subjects with the highest leukocyte 
count had longer time from onset to baseline NCCT and this 
may have influenced our analyses because of the known, 
inverse relationship between time from symptom onset to 
baseline imaging and the risk of hematoma expansion.17 
However, the association between leukocyte count and 
the risk of hematoma expansion remained significant after 
adjusting for time from onset to NCCT in the multivariable 
regression model.
Neuroinflammation and leukocyte infiltration of the hema-
toma have been the main targets of several neuroprotective 
Table 1. Baseline Characteristics of the Study Population 
(n=1302)
Age, median (IQR), y 75 (64–82)
Sex, male, n (%) 727 (55.8)
History of hypertension, n (%) 1041 (80.0)
History of diabetes mellitus, n (%) 296 (22.6)
History of hypercholesterolemia, n (%) 542 (41.6)
Antiplatelet treatment, n (%) 614 (47.2)
Anticoagulant treatment, n (%) 283 (21.7)
Time from symptom onset to NCCT, median 
(IQR), h
4.4 (1.9–8.0)
Time from onset to blood sample, median 
(IQR), h
3.4 (1.6–6.5)
WBC count, median (IQR), 1,000 cells/μL 9.2 (7.1–11.7)
Admission leukocytosis, n (%) 413 (31.7)
Baseline ICH volume, median (IQR), mL 14 (5–34)
Presence of IVH, n (%) 572 (43.9)
Hematoma expansion, n (%) 207 (15.9)
ICH indicates intracerebral hemorrhage; IQR, interquartile range; IVH, 
intraventricular hemorrhage; NCCT, noncontrast computed tomography; and 
WBC, white blood cells.
Figure 1. Cohort selection process. ICH indi-
cates intracerebral hemorrhage; IVH, intra-
ventricular hemorrhage; NCCT, noncontrast 
computed tomography; and WBC, white 
blood cells.
 at UniversitÃƒÂ  degli Studi di Brescia on May 23, 2016http://stroke.ahajournals.org/Downloaded from 
4  Stroke  June 2016
strategies in patients with ICH.35–37 However, a distinction 
between acute inflammatory response and chronic inflam-
mation should be made. Although the latter is a proven 
determinant of secondary damage in ICH,20,38 acute inflam-
mation and ICH invasion by leukocytes may be beneficial in 
preventing further hematoma expansion. Furthermore, the 
divergent effect of neutrophils and monocytes on hematoma 
expansion highlights the complexity of the acute inflam-
matory response after an ICH and suggests that future 
therapeutic strategies should focus on fine modulation of 
the immune response rather than broad, nonselective anti-
inflammatory treatment.
Our results have important implications for future studies 
and open new areas of investigation in the field of inflamma-
tion in ICH. First, to define possible therapeutic targets, further 
studies are needed to characterize the biological mechanisms 
underlying the relationships between neutrophils, monocytes, 
and hematoma expansion. Second, microglia and astrocytes 
are key players in central nervous system inflammation and 
little is known about the interaction between peripheral leu-
kocytes and central nervous system immune cells.31,35 Third, 
several promising imaging techniques can potentially provide 
in vivo images of central nervous system inflammation and 
may improve our understanding of the inflammatory response 
after ICH.39
Finally, from a clinical perspective, hematoma expansion 
is a potentially modifiable determinant of ICH outcome3,4 and 
limiting further bleeding is an appealing therapeutic strategy.40 
Hematoma expansion occurs in the first hours after an ICH 
and therefore early identification of patients with the highest 
risk of expansion is necessary. Current hematoma expansion 
predictive models are mainly based on clinical and imaging 
markers.17,41,42 Neutrophil and monocyte counts are cheap, 
fast, and widely available biomarkers that might improve our 
ability to stratify the risk of hematoma expansion in clinical 
practice.
Table 2. Comparison of Demographic and Clinical Characteristics Between WBC Quartiles (n=1302)
WBC Quartiles, 1000 Cells/μL
Q1, <7.10  
(n = 326)
Q2, 7.10–9.19  
(n = 319)
Q3, 9.20–11.70  
(n = 328)
Q4, >11.70  
(n = 329) P Value
Age, median (IQR), y 75 (65–81) 75 (65–82) 76 (65–83) 74 (62–81) 0.138
Sex, male, n (%) 193 (59.2) 187 (58.6) 175 (53.4) 172 (52.3) 0.171
History of hypertension, n (%) 256 (78.5) 249 (78.1) 267 (81.4) 269 (81.8) 0.526
History of diabetes mellitus, n (%) 83 (25.5) 65 (20.4) 66 (20.1) 82 (24.9) 0.207
History of hypercholesterolemia, n (%) 148 (45.4) 138 (43.3) 135 (41.2) 121 (36.8) 0.140
Antiplatelet treatment, n (%) 153 (46.9) 150 (47.0) 150 (45.7) 161 (48.9) 0.875
Anticoagulant treatment, n (%) 76 (23.3) 71 (22.3) 67 (20.4) 69 (21.0) 0.808
Time from symptom onset to NCCT, 
median (IQR), h
3.1 (1.6–6.8) 4.0 (1.9–9.9) 4.6 (1.9–8.4) 5.1 (3.0–7.9) 0.002
Time from onset to blood sample, 
median (IQR), h
2.4 (1.2–5.0) 3.9 (1.8–8.3) 3.5 (2.0–6.5) 4.1 (2.3–6.5) <0.001
PLT count, median (IQR), 1000 
cells/μL
197 (154–240) 221 (178–258) 230 (191–277) 255 (209–325) <0.001
aPTT, median (IQR), s 26.3 (23.8–30.3) 26.2 (23.7–29.1) 26.1 (23.6–29.4) 25.3 (23.1–29.0) 0.091
INR, median (IQR) 1.1 (1.0–1.3) 1.1 (1.0–1.3) 1.1 (1.0–1.2) 1.1 (1.0–1.2) 0.620
Baseline ICH volume, median (IQR), mL 10 (4–26) 11 (4–28) 16 (6–36) 22 (7–48) <0.001
Presence of IVH, n (%) 122 (37.4) 113 (35.4) 152 (46.3) 185 (56.2) <0.001
Hematoma expansion, n (%) 69 (21.2) 47 (14.7) 46 (14.0) 45 (13.7) 0.027
aPTT indicates activated partial thromboplastin time; ICH, intracerebral hemorrhage; INR, international normalized ratio; IQR, interquartile range; IVH, intraventricular 
hemorrhage; NCCT, noncontrast computed tomography; PLT, platelet; and WBC, white blood cells.
Table 3. Multivariable Analysis of Predictors of Hematoma 
Expansion
OR (95% Wald CI) P Value
Baseline ICH volume 
> 30 mL
4.69 (3.12–7.06) <0.001
Time from onset to 
baseline NCCT < 6 h
5.51 (3.15–9.66) <0.001
Anticoagulant 
treatment
4.40 (2.84–6.82) <0.001
Total WBC count* 0.91 (0.86–0.96) 0.001
  Neutrophil count 0.90 (0.85–0.96) 0.001
  Lymphocyte count 0.96 (0.79–1.17) 0.718
  Monocyte count 2.71 (1.08–6.83) 0.034
CI indicates confidence interval; ICH, intracerebral hemorrhage; NCCT, 
noncontrast computed tomography; OR, odds ratio; and WBC, white blood cells.
*OR for 1000 cells increase.
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Some limits of this study should be considered. First, 
our results are derived from a retrospective, single-center 
analysis. Second, the subjects screened and included were 
enrolled over a long-time course and changes in ICH man-
agement in this period may have influenced our results. 
Third, a significant proportion of the screened subjects 
were excluded because of missing follow-up NCCT or 
missing admission complete WBC count, introducing a 
potential bias. Finally, although unlikely, the observed ele-
vation in WBC count may be the consequence of chronic 
inflammatory disorders or acute infections and we were 
not able to control for these potential confounders in our 
analysis.
Conclusion
Monocyte count, as opposed to neutrophil count, is associ-
ated with higher risk of hematoma expansion. Our findings 
highlight the role of inflammation and leukocyte activation 
in coagulation after acute ICH and may offer an opportu-
nity for early identification and treatment of patients at 
high risk of hematoma expansion in clinical practice.
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